Safety and effectiveness of disease-modifying therapies after switching from natalizumab.
Zeineddine M, Al-Roughani R, Farouk Ahmed S, Khoury S, El-Ayoubi N, Al-Mahdawi A, Al-Khabouri J, Al-Asmi A, Chentouf A, Inshasi J, Gouider R, Mrabet S, Shalaby N, Massouh J, Mohamed Ramzy Hasan Mohamed F, Al-Hajje A, Salameh P, Dimassi H, Boumediene F, Yamout B.
Zeineddine M, et al.
Mult Scler. 2024 Jul;30(8):1026-1035. doi: 10.1177/13524585241261565. Epub 2024 Jul 26.
Mult Scler. 2024.
PMID: 39054846